CION Ameerpet
Liposarcoma Subtype · Diagnosis & Treatment · NABH Accredited
Myxoid Liposarcoma Explained
If a biopsy report has used the words "myxoid liposarcoma" — or the longer phrase "myxoid round-cell liposarcoma" — you are looking at a specific, well-defined subtype of fat-forming soft tissue sarcoma, not a vague diagnosis. It most often appears as a slow-growing, painless deep lump in the thigh of an adult between 30 and 50, it is driven by a single recognisable gene fusion (FUS-DDIT3), and its behaviour is unusual in two ways: it is strikingly sensitive to radiation, and it can spread to other fatty sites and the spine rather than only the lungs. This guide explains what the diagnosis means, how the round-cell percentage decides its grade, and how CION's sarcoma team treats it across 7 NABH-accredited Hyderabad locations.
- A defined molecular subtype — confirmed by the FUS-DDIT3 (or EWSR1-DDIT3) gene fusion, not guesswork
- Round-cell percentage decides grade — a low-round-cell tumour is far less aggressive than a high-round-cell one
- Unusually radiosensitive — radiation often shrinks it dramatically and is built into the plan
- Specialist follow-up — surveillance covers fat, spine and bone marrow, not just chest CT
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What Is Myxoid Liposarcoma?
Myxoid liposarcoma is one of the four main types of liposarcoma — the family of soft tissue sarcomas that arise from fat-forming (adipocytic) cells. The word "myxoid" describes what the pathologist sees: a tumour set in a gel-like, mucin-rich background, threaded by a delicate "chicken-wire" network of fine blood vessels. It accounts for roughly a third of all liposarcomas and, unlike the well-differentiated and dedifferentiated subtypes that favour the abdomen, it has a strong preference for the deep soft tissues of the limbs — above all the thigh.
It is also a cancer of relatively younger adults. Most people diagnosed with myxoid liposarcoma are between 30 and 50 years old — about a decade younger than the typical liposarcoma patient — and men and women are affected roughly equally. That younger age, combined with how slowly the tumour often grows, is one reason a myxoid liposarcoma is sometimes mistaken for a harmless lipoma or a sports injury for months before it is properly investigated.
Importantly, myxoid liposarcoma is not inherited. It is driven by an acquired change inside the tumour cells — a chromosomal swap that fuses two genes — and there is nothing a patient did, ate, or was exposed to that caused it. Understanding it as a distinct subtype matters, because its diagnosis, grading and treatment differ in real ways from the other liposarcomas described on our sarcoma — overview hub.
Did You Know? Myxoid liposarcoma is one of the very few sarcomas that can be confirmed almost to certainty by a single genetic test. More than 90 percent of these tumours carry the FUS-DDIT3 gene fusion (a small number carry the related EWSR1-DDIT3). Finding that fusion on a molecular test (FISH or PCR) all but seals the diagnosis — which is exactly why a sarcoma centre will often send the biopsy for this test rather than rely on the microscope alone.
Symptoms: How Myxoid Liposarcoma Usually Shows Up
The classic presentation is quietly deceptive. Myxoid liposarcoma tends to announce itself as a painless, gradually enlarging lump deep in the thigh — soft to firm, often quite large by the time it is noticed precisely because it sits beneath the muscle rather than just under the skin. Pain, numbness or weakness usually appear late, only once the mass is big enough to press on a nerve or blood vessel.
Because it grows slowly and feels soft, it is one of the sarcomas most often confused with something benign. The warning signs that should prompt a specialist scan are the same ones that apply to any suspicious soft tissue lump:
- A lump that is larger than 5 cm, or one that keeps slowly getting bigger over weeks to months
- A lump that sits deep to the muscle fascia rather than freely mobile just under the skin
- A lump that is painless — a sarcoma being painless does not make it harmless
- A "lipoma" that has been watched for years and has recently changed or started to grow
If any of these apply, the correct next step is an MRI and an image-guided needle biopsy at a sarcoma centre — never a quick "let's just remove it" excision at a general clinic, which can compromise the eventual margin. For the full surgical picture, see how CION approaches sarcoma treatment in Hyderabad.
Myxoid vs Round-Cell: Why the Percentage Decides Everything
The single most important number on a myxoid liposarcoma report is the round-cell percentage. The same tumour can sit anywhere on a spectrum: at one end, a pure "low-grade" myxoid tumour made almost entirely of bland cells in a gel-like matrix; at the other, a tumour densely packed with small, primitive round cells. Because the two ends behave so differently, pathologists historically described the aggressive end as myxoid round-cell liposarcoma — and it is the proportion of round cells, not the size of the lump, that drives the grade and the outlook.
Lower grade
Pure / Low Round-Cell (<5%)
A tumour with little or no round-cell component is treated as low-grade. It still requires complete surgical removal, but the risk of it spreading to distant sites is comparatively low, and surgery with radiation often gives excellent local control.
Higher grade
High Round-Cell (>5%)
Once the round-cell component rises above roughly 5 percent — and especially beyond 25 percent — the tumour behaves more aggressively, with a meaningfully higher chance of spreading. These tumours are the ones most likely to be offered chemotherapy alongside surgery and radiation.
Why it is measured
Grade Guides the Plan
The round-cell percentage feeds directly into the tumour grade and therefore into how intensively the cancer is treated and followed up. This is why getting the percentage right — through expert sarcoma pathology — is not a technicality; it changes the treatment.
A second feature pathologists look for is tumour necrosis (areas of dead tumour), which, together with a high round-cell count, pushes a tumour firmly into the high-grade category. This is also why a specialist pathology second opinion can be so valuable in myxoid liposarcoma: a few percentage points either side of the round-cell threshold can be the difference between adding chemotherapy or not.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a Specialist Plan for Myxoid Liposarcoma
Because myxoid liposarcoma is radiosensitive and spreads in unusual ways, it benefits more than almost any other sarcoma from a coordinated surgery-plus-radiation plan agreed at a tumour board. Talk to CION across 7 Hyderabad locations with same-week appointments.
How Myxoid Liposarcoma Is Diagnosed
Confirming myxoid liposarcoma is a stepwise process. The order matters: the wrong first step — removing the lump before it is studied — can compromise the surgical margin and the whole treatment that follows.
Step 1 — MRI of the Primary Site
MRI is the imaging investigation of choice. Myxoid liposarcoma has a fairly characteristic look on MRI — a high-signal, "fluid-like" mass on certain sequences because of its gel-rich matrix, often with fatty and lacy septal components. The scan also maps the tumour's exact size, depth, and relationship to nerves and vessels, which is what the surgeon needs to plan a margin-clear, limb-sparing removal.
Step 2 — Image-Guided Core Needle Biopsy
A core needle biopsy is taken under ultrasound or CT guidance to confirm the diagnosis before any surgery. At a sarcoma centre the needle track is positioned so it can be removed within the eventual excision — track planning is part of margin planning. The pathologist then assesses the cell type, the round-cell percentage, and any necrosis.
Step 3 — Molecular Confirmation (FUS-DDIT3)
Where the microscope leaves any doubt, a molecular test (FISH or RT-PCR) looks for the FUS-DDIT3 (or EWSR1-DDIT3) gene fusion that defines this subtype. A positive result is close to diagnostic and also helps distinguish a high-round-cell myxoid liposarcoma from other small-round-cell tumours that need very different treatment.
Step 4 — Staging for Unusual Spread
Most sarcomas are staged with a chest CT to look for lung spread. Myxoid liposarcoma needs more. Because it has a documented habit of spreading to other fatty soft tissue sites, the abdomen, and the spine and bone marrow — sometimes before the lungs — staging may add a whole-body or spine MRI, and sometimes a PET scan, to catch metastases that a chest CT alone would miss.
A key point for patients: if a thigh "lipoma" has already been shelled out at a general clinic and the report unexpectedly reads "myxoid liposarcoma," the surgical bed is now considered contaminated. A planned re-excision and proper staging by a sarcoma specialist are usually needed — do not assume that a removed lump is the end of the story.
How Myxoid Liposarcoma Is Treated
Treatment is decided at a multidisciplinary tumour board and tailored to the round-cell percentage. The three pillars below are combined according to grade, size and location.
The foundation
Surgery — Wide Local Excision
Complete removal with clear (R0) margins is the cornerstone of cure. For a thigh tumour this is almost always limb-sparing surgery — the tumour and a cuff of healthy tissue are removed while the leg and its function are preserved.
Its special strength
Radiation Therapy
Myxoid liposarcoma is unusually radiosensitive. Pre-operative (neoadjuvant) radiation can shrink the tumour markedly and protect a tight margin; post-operative radiation improves local control. Radiation is part of the plan far more often here than in other sarcomas.
For higher-grade disease
Chemotherapy
For high round-cell or metastatic disease, chemotherapy is considered. Myxoid liposarcoma is notably responsive to trabectedin and to anthracycline-based regimens — a sensitivity that is more favourable than in many other soft tissue sarcomas.
The art of treating myxoid liposarcoma is sequencing these three pillars correctly. Putting radiation before surgery in a radiosensitive tumour, or reserving chemotherapy for the genuinely high-grade cases, is the kind of decision that should be made at a sarcoma tumour board — not by any single doctor in isolation.
Where It Spreads, and What the Outlook Is
One of the things that sets myxoid liposarcoma apart from almost every other sarcoma is where it travels. Most soft tissue sarcomas spread first and foremost to the lungs. Myxoid liposarcoma, by contrast, has a recognised tendency to seed other fatty (adipose) soft tissue — the opposite limb, the abdomen and retroperitoneum, the chest wall — and the spine and bone marrow, sometimes producing bone metastases that never show up on a chest CT. This is precisely why CION's surveillance for this subtype deliberately looks beyond the lungs.
The outlook depends heavily on the round-cell percentage. A pure, low-round-cell myxoid liposarcoma that is completely removed with clear margins carries a genuinely favourable prognosis, with most patients doing well over the long term. As the round-cell component and any tumour necrosis rise, the risk of metastasis climbs — which is why high-round-cell tumours are treated more aggressively from the outset and followed more closely afterwards.
Follow-Up Tailored to This Subtype
After treatment, surveillance combines regular MRI of the surgical site to catch a local recurrence early with imaging aimed at this subtype's unusual spread — periodic whole-body or spine MRI and chest imaging. Because metastases can appear several years later, follow-up for myxoid liposarcoma is generally continued for longer than for many other cancers.
Indicative Cost in Hyderabad
| Procedure / Investigation | Approx. Cost (INR) | Notes |
|---|---|---|
| MRI (diagnosis & surgical planning) | ₹6,000 – ₹20,000 | Dedicated soft tissue protocol; the key imaging test |
| Core Needle Biopsy (track-planned) | ₹8,000 – ₹25,000 | Image-guided; needle line positioned to be excised |
| Molecular Test (FUS-DDIT3 FISH/PCR) | ₹12,000 – ₹30,000 | Confirms the subtype when the microscope is uncertain |
| Wide Local Excision (limb-sparing) | ₹1,50,000 – ₹5,00,000 | Varies by tumour size, depth, and reconstruction |
| Radiation (IMRT/IGRT) | ₹1,20,000 – ₹2,50,000 | Neoadjuvant or adjuvant; this tumour is radiosensitive |
Costs are indicative. A personalised estimate is provided after your CION consultation. EMI options and cashless support through major TPAs, Aarogyasri, CGHS, ECHS & ESI are available for eligible patients.
Did You Know? A standard chest CT can give false reassurance in myxoid liposarcoma. Because this subtype favours spreading to fat and the spine rather than the lungs, a clear chest scan does not rule out metastasis. That is why specialist follow-up adds spine or whole-body MRI — and why being looked after at a centre that knows this subtype's habits genuinely changes how safely it is monitored.
Why Patients Choose CION for Myxoid Liposarcoma
A subtype this specific deserves a team that understands its biology. Here is why patients trust CION with myxoid and round-cell liposarcoma.
AIIMS-trained surgical oncologist
Molecular confirmation when needed
Round-cell % and grade re-read
Radiation built into the plan
Surveillance beyond the chest
Tumour board for every case
7 NABH-accredited Hyderabad locations
EMI facility & insurance accepted
4.8 / 5 Google rating
Take The Next Step
Talk to a Sarcoma Team That Knows This Subtype
Whether you have just been diagnosed or are holding a report you do not fully understand, CION's sarcoma team will explain your round-cell grade and map out a clear, tailored plan for your myxoid liposarcoma.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Myxoid Liposarcoma — Frequently Asked Questions
Is myxoid liposarcoma curable?
Yes — a localised myxoid liposarcoma is very often curable, especially the pure, low-round-cell form. The cornerstone is complete surgical removal with clear (R0) margins, usually as limb-sparing surgery, combined with radiation to which this tumour is unusually sensitive. The outlook is most favourable when the round-cell component is low and the tumour is fully removed; it becomes more guarded as the round-cell percentage and any tumour necrosis rise. Because this subtype can spread years later, long-term specialist follow-up is part of giving the best chance of cure.
What is the difference between myxoid liposarcoma and myxoid round-cell liposarcoma?
They are two ends of the same tumour. "Myxoid liposarcoma" describes the low-grade form — bland cells set in a gel-like matrix with a delicate vascular network. As the proportion of small, primitive round cells rises (above roughly 5 percent, and especially beyond 25 percent), the same tumour behaves more aggressively and is described as myxoid round-cell liposarcoma. The round-cell percentage is the most important number on the report because it decides the grade, whether chemotherapy is added, and how closely you are followed up.
Where does myxoid liposarcoma spread?
Unlike most sarcomas, which spread mainly to the lungs, myxoid liposarcoma has a recognised tendency to spread to other fatty (adipose) soft tissue — the opposite limb, the abdomen and retroperitoneum, the chest wall — and to the spine and bone marrow. Bone and soft-tissue metastases can appear before any lung involvement, which is why staging and follow-up for this subtype add spine or whole-body MRI rather than relying on a chest CT alone.
Does myxoid liposarcoma respond to radiation?
Yes, markedly. Myxoid liposarcoma is one of the most radiosensitive of the soft tissue sarcomas. Radiation given before surgery (neoadjuvant) can shrink the tumour considerably, helping the surgeon achieve a clear margin and preserve the limb; radiation given after surgery (adjuvant) improves local control. Because of this responsiveness, radiation is built into the treatment plan for myxoid liposarcoma far more often than for other sarcoma subtypes.
How is myxoid liposarcoma diagnosed and confirmed?
Diagnosis begins with an MRI of the lump, followed by an image-guided core needle biopsy taken before any surgery, so the pathologist can assess the cell type and round-cell percentage. Where the microscope leaves doubt, a molecular test (FISH or RT-PCR) looks for the FUS-DDIT3 (or EWSR1-DDIT3) gene fusion that defines this subtype — a positive result is close to diagnostic. Staging then looks beyond the lungs, often adding spine or whole-body MRI, because of this tumour's unusual spread.